Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Guojing ZhangDivision of Hematology and Oncology, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA.
Abbe PannucciDivision of Hematology and Oncology, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA.
Andrey A IvanovDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0001-7476-1329
Jeffrey SwitchenkoBiostatistics Shared Resource of Winship Cancer Institute, Atlanta, GA 30322, USA.
Shi-Yong SunDepartment of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA 30322, USA.ORCID 0000-0002-0117-8826
Gabriel L SicaDepartment of Pathology, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA.
Zhentao LiuDivision of Hematology and Oncology, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA.ORCID 0000-0002-1061-7042
Yufei HuangDivision of Hematology and Oncology, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA.
John C SchmitzDivision of Hematology and Oncology, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA.ORCID 0000-0001-6321-9606
Taofeek K OwonikokoDivision of Hematology and Oncology, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA.
Funding
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Vu H. Duong · 2008 to 2026
$51.0M
Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Project 3: Targeting Bax signaling to overcome treatment resistance in NSCLCP50CA217691 · NCI · EMORY UNIVERSITY · PI DENG, XINGMING · 2019 to 2024
$10.1M
Targeting polo-like kinase for therapy of small cell lung cancerR01CA273216 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Taofeek K Owonikoko · 2022 to 2026
$2.5M
Predicting actionable cancer vulnerabilities enabled by mutant-directed protein-protein interactionsR21CA274620 · NCI · EMORY UNIVERSITY · PI IVANOV, ANDREY · 2022 to 2023
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Polo-like Kinase 1 Inhibitors Demonstrate In Vitro and In Vivo Efficacy in Preclinical Models of Small Cell Lung Cancer. · full record | OpenQuestion